AKTS Stock Aktis Oncology (AKTS, $21.94) entered Uptrend as Momentum indicator ascends above 0 level on Jun 12, 2026
at Tickeron.com
This indicator may be signaling that AKTS's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 66 similar cases where AKTS's Momentum Indicator exceeded 0, and of them led to a successful outcome. Odds of Success:
AKTS in upward trend: price rose above 50-day moving average on June 11, 2026
AKTS moved above its 50-day moving average on June 11, 2026 date and that indicates a change from a downward trend to an upward trend. In of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 12, 2026. You may want to consider a long position or call options on AKTS as a result. In of 65 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AKTS just turned positive on June 12, 2026. Looking at past instances where AKTS's MACD turned positive, the stock continued to rise in of 32 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AKTS advanced for three days, in of 203 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 76 cases where AKTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
AKTS broke above its upper Bollinger Band on June 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.631) is normal, around the industry mean (20.056). P/E Ratio (0.000) is within average values for comparable stocks, (35.868). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). AKTS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (161.290) is also within normal values, averaging (361.304).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.